This study evaluated the sensitivities of gastric cancer cells to various chemotherapy drugs, and investigated the relationship between the expression of Pglycoprotein (P-gp) and multidrug resistance-associated protein (MRP) and multidrug resistance. Drug sensitivities were determined using a methyltetrazolium assay: expression levels of Pgp and MRP were measured using immunohistochemistry. On purification culture, gastric cancer cells were found to be most sensitive to cisplatin, mitomycin and adriamycin, moderately sensitive to etoposide and 5-fluorouracil, and less sensitive to homocamptothecin and methotrexate, with sensitivities of 76.7%, 70.0%, 66.7%, 60.0%, 56.7%, 43.3% and  30 .0%, respectively. Positive expression for P-gp and MRP in gastric cancer tissues was 41.7% and 29.2%, respectively; coexpression of P-gp and MRP in cancer tissue was 23%. The drug-resistant groups had higher positive expression of P-gp and MRP compared with the drug-sensitive groups. In conclusion, expression of P-gp and MRP seems to be associated with multidrug resistance in gastric cancer.
Introduction
Gastric cancer is one of the most common cancers worldwide; 1 the incidence is particularly high in Asian countries, including China. Surgery is effective treatment in the majority of cases, but chemotherapy plays an important role in patients with advanced gastric cancer. 2, 3 Although a number of chemotherapeutic agents have been used in the treatment of gastric cancer, the occurrence of drug resistance, especially resistance to multiple drugs, decreases their efficacy in a large proportion of cases. 4 Multidrug resistance (MDR) is a serious problem in chemotherapy and is one of the main reasons for a poor outcome. Overexpression of two adenosine triphosphate (ATP)-dependent drug transporter proteins, P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP), is associated with MDR in several soft tissue P-glycoprotein and MRP in gastric cancer sarcomas. 4, 5 Both proteins belong to the ATPbinding cassette protein superfamily and cause efflux of anticancer agents out of cells, thereby decreasing their intracellular accumulation. 6 -8 A large number of studies has revealed that diverse mechanisms can be involved in the development of MDR, including extrusion of the drug by cell membrane pumps, an increase in drug detoxification or DNA damage repair, redistribution of intracellular accumulation of drugs, modification of drug target molecules, suppression of drug-induced apoptosis and up-regulation of lipids, as well as other biochemical changes. 9 -11 To date, however, the precise mechanisms of MDR have not been completely elucidated and the clinicopathological relevance of P-gp and MRP in gastric cancer remains unknown.
The present study was designed to investigate the expression of P-gp and MRP in gastric cancer cells using immunohistochemistry. The sensitivities of the gastric cancer cells to various chemotherapy drugs were then evaluated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide) assay, in order to investigate the relationship between P-gp and MRP expression and multidrug resistance.
Patients and methods

PATIENTS
Patients with a histopathological diagnosis of gastric cancer who were attending the Provincial Hospital Affiliated to Shandong University, Jinan, China, for treatment between 1999 and 2001 were enrolled sequentially into the study. None of the patients included in the study had received prior chemotherapy. The cancers were evaluated according to the tumour-nodemetastases (TNM) classification. 12 Written informed consent was obtained from all the study participants. The study protocol was approved by the Ethics Review Committee of the Central Laboratory, Shandong University, Jinan, China.
ISOLATION OF GASTRIC CANCER CELLS
Gastric cancer samples were collected by surgical resection. Samples were also collected from metastatic lymph nodes in some of the cases studied. After removal of the attached tissues, the sample was digested with 0.3% collagenase type IV (Gibco ® , Invitrogen™ Life Science, Gaithersburg, MD, USA) for 4 h. Isolated primary gastric cancer cells were cultured in RPMI 1640 (Gibco ® ) containing 10% fetal bovine serum (Sijiqing Pharmacia Biotech Co. Ltd, Hangzhou, China) with a seeding density of 3 -5 × 10 5 cells/ml. Cultures were maintained at 37°C in an atmosphere of 5% CO 2 and the medium was changed every 3 days. The cells were grown on coverslips in wells for later immunocytochemical staining. Expression of cytokeratin was determined using immunocytochemistry to confirm the identity of the gastric cancer cells. Cells on the coverslips were blocked by incubating with 0.3% hydrogen peroxide in 90% methanol for 30 min at 4°C and then with normal serum for 45 min at 4°C. After washing in 10 mM phosphatebuffered saline (PBS, pH 7.3), they were incubated overnight at 4°C with a primary polyclonal antibody against cytokeratin (1:100 dilution; Boshide Biotechnology Co. Ltd, Wuhan, China), then washed three times in 10 mM PBS before being incubated with a secondary biotin-conjugated goat antirabbit antibody (Vector Laboratories, Burlingame, CA, USA) for 60 min at 37°C, and washed a final three times in 10 mM PBS. Immunoreactive cells were then visualized using a Vectastain ® ABC-PO (rabbit immunoglobulin G) kit (Vector Laboratories). P-glycoprotein and MRP in gastric cancer
IN VITRO DRUG SENSITIVITY TEST
Cells from primary gastric cancers and metastatic lymph nodes were seeded in 96well plates at a density of 8 × 10 3 cells/well. After 24 h, freshly prepared anticancer drugs -adriamycin (ADM), mitomycin (MMC), 5fluorouracil (5-FU), etoposide (VP-16), cisplatin (DDP), methotrexate (MTX) and homocamptothecin (HCPT) -were added to the culture medium at the human peak plasma concentrations of 0.4, 3.0, 10.0, 30.0, 3.0, 4.0 and 2.0 µg/ml, respectively. After incubation with the drugs for 48 h, 5 mg/ml MTT (Sigma-Aldrich, St Louis, MO, USA) was added to the wells. After 4 h, dimethyl sulphoxide (Hua Mei Industrial Co. Ltd, Shanghai, China) was added to the wells and optical densities were read at a wavelength of 570 nm using a microplate reader (Biohit BP-800; Biohit Oyj, Helsinki, Finland). The control group comprised cells incubated in culture medium without any drug treatment followed by addition of dimethyl sulphoxide as described above, and the blank group comprised cells incubated in culture medium alone. Cell viability was measured in triplicate for each group. The inhibition rate (IR) was calculated as: IR = ([absorbance value in control groupabsorbance value in drug-treated group]/[absorbance value in control groupabsorbance value in blank group]) × 100%. An IR ≥ 30% was considered to indicate sensitivity to the drug being tested, whereas an IR < 30% was considered to indicate drug resistance. The sensitivity rates to each drug were calculated based on short-term culture (of primary gastric cancer cells, including non-tumour cells) and purification culture (of isolated primary gastric cancer cells only). As purification culture was deemed to be more meaningful than short-term culture, the best measure of the sensitivity rate was considered to be that based on purification culture and was calculated as: (number of samples with an IR ≥ 30%)/(total number of samples) × 100.
DETECTION OF P-GP AND MRP EXPRESSION
Tumour samples consisting of cancer and para-cancer cells were fixed with 10% formaldehyde, embedded in paraffin and cut into 3 µm sections. Briefly, the tissue sections were blocked with 0.3% hydrogen peroxide in 90% methanol and then incubated separately with a monoclonal antibody to P-gp (1:100 dilution; BioGenex Laboratories, San Ramon, CA, USA) or MRP (1:400 dilution; Chemicon, Temecula, CA, USA) at 4°C overnight, washed three times with 1 × PBS, pH 7.2, then incubated with biotinylated antimouse immunoglobulin G (1:100 dilution; Boshide) for 30 min at 4°C. The tissue sections were washed three times with TB buffer (300 mM sodium chloride, 300 mM sodium citrate), pH 8.0, and then incubated with biotinylated horseradish peroxidase solution for 30 min at 37°C (Boshide Biotechnology Co. Ltd). Finally, the slides were stained with diaminobenzidine (Boshide Biotechnology Co. Ltd) and observed using a light microscope.
The presence of brown deposits indicated P-gp and MRP expression. Cancer or paracancer tissues were considered to be positive for P-gp and MRP expression if obvious cell staining was present in ≥ 10% of the cells. Staining seen in < 10% of the cells was considered to indicate a negative result.
STATISTICAL ANALYSIS
Data analyses were performed using the SPSS ® statistical package, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Correlations between P-gp and MRP expression and multidrug resistance were P-glycoprotein and MRP in gastric cancer tested using Fisher's exact test. Other data were analysed using the Student's t-test. A Pvalue < 0.05 was considered to be statistically significant.
Results
PATIENTS AND SAMPLE COLLECTION
A total of 48 patients with gastric cancer were enrolled in the study, comprising 33 males and 15 females with a mean ± SD age of 51.5 ± 11.6 years (range 27 -71 years). Histopathological diagnoses included welldifferentiated adenocarcinoma (n = 2), moderately differentiated adenocarcinoma (n = 8), poorly differentiated adenocarcinoma (n = 33), mucinous adenocarcinoma (n = 4) and signet ring cell carcinoma (n = 1). According to the TNM classification, 12 six cases were stage I, nine were stage II, 22 were stage III, and 11 were stage IV. Samples were collected from metastatic lymph nodes in four cases.
ISOLATION OF GASTRIC CANCER CELLS
Examples of primary gastric cancer cells isolated from tumour tissues are shown in Fig. 1 . The primary cells showed notable heterogeneity in appearance and size. Cytokeratin expression was confirmed by immunocytochemistry.
DRUG SENSITIVITY TESTS
The IRs for DDP, MMC, ADM, VP-16, 5-FU, HCPT and MTX were 45.3%, 42.2%, 42.7%, 38.7%, 36.9%, 32.9% and 27.8%, respectively. The number of successfully cultured samples was 48 using the shortterm culture method and 30 using the purification culture method. The sensitivity rates of samples from the short-term and purification culture methods that had an IR ≥ 30% to the different drugs are shown in Table 1 . Using the purification culture method, the sensitivity rates of gastric cancer cells to DDP, MMC, ADM, VP-16, 5-FU, HCPT 
P-GP AND MRP EXPRESSION
Both P-gp and MRP were located at the membrane and in the cytoplasm of gastric cancer cells (Fig. 2) . Mostly, P-gp and MRP were localized within the cell, although in some cancer tissues diffuse staining was Table 2 ). Coexpression of P-gp and MRP in cancer tissue, was 23% (11/48). There was no significant difference between the expression of P-gp and MRP in cancer tissue and para-cancer tissue.
CORRELATION OF P-GP AND MRP EXPRESSION WITH DRUG SENSITIVITY
As shown in Table 3 , the positive expression rates for P-gp and MRP in cells resistant to ADM, VP-16 and HCPT were significantly higher than those in cells sensitive to these drugs; the co-expression rate was also higher in the drug-resistant cells. There was, however, no significant difference in the rates of positive P-gp and MRP expression in cells resistant to DDP, MMC, 5-FU and MTX compared with rates in cells sensitive to these drugs.
Discussion
The present study showed that gastric cancer cells were most sensitive to DDP, MMC and ADM, moderately sensitive to VP-16 and 5-FU, and least sensitive to HCPT and MTX, which does not reflect the selection of drugs commonly used in clinical practice.
Topoisomerase I (Topo I) has been shown to produce a DNA single-strand break allowing DNA relaxation for replication. 13 As a Topo I inhibitor, HCPT presented significant effects on cancer cells with MDR associated with MRP and P-gp. It has been reported that the apoptosis induced by HCPT correlates with the degree of differentiation in gastric cancer cells; 14 well-differentiated cancer cells undergo apoptosis more easily with HCPT. In the present study, sensitivity to HCPT was relatively low, which may be due to the high proportion of poorly differentiated gastric cancers.
A particular patient may not be sensitive to a certain drug that has high effectiveness in most gastric cancer cases. Conversely, a drug may have no effect in the majority of cases, but show great efficacy in some individual cases. It is, therefore, necessary to use drug sensitivity tests to guide chemotherapy in clinical practice. It should be noted that the in vitro drug concentrations in the present study may not have been equivalent to in vivo concentrations.
Comparisons of samples from metastatic lymph nodes with their corresponding primary tumours in the present study No statistically significant difference between the expression of P-gp and MRP in cancer tissue and paracancer tissue (P > 0.05). P-glycoprotein and MRP in gastric cancer 15 studied the sensitivity of eight cases of primary colon cancer with secondary hepatic metastasis to six different drugs. They demonstrated that the metastatic tissues had lower sensitivities than the primary tissues and the sensitivities of metastatic tissues were not correlated with those of primary tissues. Thus, drug sensitivity tests on metastatic tissues may be unlikely to indicate the sensitivity of the primary tissues.
Recently, attention has been focused on MDR and its ability seriously to limit the effectiveness of chemotherapy. 16 -19 Overexpression of P-gp, an integral membrane protein, represents one of the major mechanisms that contribute to the MDR phenotype. 20 -22 As a drug efflux pump that actively transports drugs from the inside to the outside of cells, P-gp causes a defect in the intracellular accumulation of drugs necessary for cancer cell killing. In the present study, positive expression of P-gp and MRP in gastric cancer tissues was 41.7% and 29.2%, respectively, and co-expression of P-gp and MRP in cancer tissue was 23%. The ADM, VP-16 and HPCT drug-resistant groups had higher positive expression of Pgp and MRP compared with the drugsensitive groups, indicating that expression of P-gp and MRP may be associated with MDR in gastric cancer.
In summary, drugs for chemotherapy can be selected on the basis of drug sensitivity tests to avoid primary MDR. The inhibition of P-gp and MRP expression may reverse the MDR phenotype thereby enhancing intracellular accumulation of anticancer drugs necessary for cancer cell killing.
